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Abstract
Atherosclerosis is considered a chronic inflammatory disease in which monocytes and macrophages are critical.
These cells express CD14, toll-like receptor (TLR) 2, and TLR4 on their surfaces, are activated by minimally modified
low-density lipoprotein (mmLDL) and are capable of secreting pro-inflammatory cytokines. The aim of this research
was thus to demonstrate that the activation of CD14, TLR2, and TLR4 by mmLDL induces the secretion of
cytokines.
Methods: Human monocytes and macrophages were incubated with monoclonal antibodies specific for CD14,
TLR4, and TLR2 prior to stimulation with mmLDL. Cytokine secretion was then compared to that observed upon
mmLDL stimulation in untreated cells.
Results: Stimulation with mmLDL induced the secretion of pro-inflammatory cytokines. Blocking CD14 in
monocytes inhibited secretion of interleukin (IL)-1b (72%), IL-6 (58%) and IL-10 (63%), and blocking TLR4 inhibited
secretion of IL-1b by 67%, IL-6 by 63% and IL-10 by 60%. Blocking both receptors inhibited secretion of IL-1b by
73%, IL-6 by 69% and IL-10 by 63%. Furthermore, blocking TLR2 inhibited secretion of IL-1b by 65%, IL-6 by 62%
and IL-10 by 75%. In macrophages, we found similar results: blocking CD14 inhibited secretion of IL-1b by 59%,
IL-6 by 52% and IL-10 by 65%; blocking TLR4 inhibited secretion of IL-1b by 53%, IL-6 by 63% and IL-10 by 61%;
and blocking both receptors inhibited secretion of IL-1b by 69%, IL-6 by 67% and IL-10 by 65%. Blocking TLR2 in
macrophages inhibited secretion of IL-1b by 57%, IL-6 by 40% and IL-10 by 72%.
Conclusion: Our study demonstrates that CD14, TLR4, and TLR2 participate in the immune response against
mmLDL by inducing the production of pro-inflammatory cytokines in both monocytes and macrophages. These
findings suggest that the activation of these receptors by mmLDL contributes to the inflammatory process of
atherosclerosis.
Introduction
Several studies have shown that pro-inflammatory cyto-
kines, such as tumor necrosis factor (TNF)-a,i n t e r l e u -
kin (IL)-1b, and IL-6, play an important role in the
development of atherosclerosis [1]. Monocytes and
macrophages are innate immune cells that are central to
the inflammatory response in the atherosclerotic plaque.
These cells are the main producers of pro-inflammatory
cytokines [2,3] during the response to exogenous anti-
gens that are involved in atherosclerosis, such as Chla-
mydia pneumoniae [4], or to endogenous antigens such
as oxidized low-density lipoprotein (oxLDL), which has
been shown to play a role in the development of athero-
sclerotic plaques [5,6]. Furthermore, oxLDL is consid-
ered a pro-atherogenic molecule [7] that is capable of
inducing the secretion of TNF-a [8].
Monocytes and macrophages express CD14 and toll-
like receptors (TLRs) on the cell surface [9]. CD14 and
TLRs are pattern recognition receptors capable of acti-
vating multiple genes that encode pro-inflammatory
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such as cellular-1 vascular adhesion molecule and intra-
cellular-1 adhesion molecule, and co-stimulatory mole-
cules such as CD80 in response to pathogens or
molecular patterns associated with pathogens [10].
Some studies have demonstrated the participation of
the TLRs in the development of the atherosclerotic pla-
que [11,12], and previous evidence suggests a potential
role for oxidized modified LDL as an endogenous anti-
gen capable of triggering and maintaining the inflamma-
tory process in the atherosclerotic plaque [5-7]. Previous
studies have also demonstrated that minimally
modified low-density lipoprotein (mmLDL) induces
TLR4-dependent secretion of MIP-2 and TLR4-
independent, MyD88-independent secretion of TNF-
a in macrophages [13]. In contrast, we and other
authors have reported that the synthesis of TNF-a is
dependent on TLR4 [14,15]. Furthermore, we demon-
strated that TLR2 also participates in the synthesis of
TNF-a in response to mmLDL [14].
The regulation of the activation of TLRs includes sev-
eral mechanisms such as the production of anti-
inflammatory cytokines, mainly IL-10 [16]. Or well by
the TLRs homologs such as RP105 protein, that inter-
acts directly with the TLR4 signaling complex, resulting
in the negative regulation of TLR4 [17]. The production
of these negative regulators, assures proper regulation of
the pro- and anti-inflammatory balance [16].
In this study, we aimed to analyze the participation of
CD14, TLR4, and TLR2 in the production of the pro-
inflammatory cytokines IL-1b and IL-6 and the anti-
inflammatory cytokine IL-10 in response to mmLDL.
We found that blocking these receptors inhibited the
production of IL-1b, IL-6, and IL-10. These results pro-
vide new perspectives on the role of oxidized modified
LDL in the inflammation associated with atherosclerosis.
Materials and methods
Informed consent was obtained from seven healthy, nor-
molipidemic 20- to 30-year-old male volunteers without
cardiovascular risk factors or clinically apparent athero-
sclerotic disease. The study was approved by the Human
Ethics and Medical Research Committee of the Instituto
Mexicano del Seguro Social and conducted according to
the guidelines of the Declaration of Helsinki.
LDL isolation and modification
Native human LDL (nLDL) (density = 1.019-1.063 g/ml)
was isolated from plasma by ultracentrifugation. The
density of the plasma was adjusted to 1.2 g/ml by add-
ing solid potassium bromide (KBr) (J.T. Baker, Phillips-
burg, NJ). Density gradients were formed in 6-ml
polycarbonate centrifuge tubes by overlaying 2 ml
plasma solution with 3 ml 0.5 mM NaCl (endotoxin-
free), pH = 7.4, d = 1.006 g/ml. The tubes were ultra-
centrifuged in a Sorvall Discovery M150 SE ultracentri-
fuge equipped with an S80AT3 fixed angle rotor at
41,500 × g for 4 hours at 4°C. After ultracentrifugation,
very low-density lipoprotein was removed, 3.0 ml of the
lower layer was transferred to another tube, 2 ml KBr-
NaCl (d = 1.18 g/ml) was added and the samples were
gently mixed. The tubes were ultracentrifuged at 41,500
× g for 4 hours at 4°C, and the LDL fraction was
removed. The LDL fraction was dialyzed against 0.5
mM NaCl, pH = 7.4, for 24 hours at 4°C to remove
EDTA. LDL was oxidized using CuSO4 (J.T. Baker). To
produce mmLDL, 300 μg/ml LDL was incubated with
10 μmol/L CuSO4 (J.T. Baker) for 1 hour at 37°C. The
mmLDL was then extensively dialyzed against 0.5 mM
NaCl, 0.5 mM EDTA, pH = 7.4, for 24 hours at 4°C.
Oxidative modification of LDL was assessed by measur-
ing thiobarbituric acid-reactive substances as previously
described [18]. This assay showed that samples con-
tained between 0.8 and 2.8 nmol malondialdehyde per
milligram of protein. The optimal concentrations of
mmLDL for activation of human monocytes and macro-
phages were 50 μg/ml and 70 μg/ml, respectively (data
not shown). All nLDL and mmLDL preparations used in
these experiments were tested for bacterial lipopolysac-
charide (LPS) contamination using a Limulus Amoebo-
cyte Lysate kit (BioWhittaker, Walkersville, MD)
according to the manufacturer’s instructions.
Monocyte isolation
Peripheral blood mononuclear cells (PBMCs) were
obtained from buffy coats by density centrifugation
using Lymphoprep (Axis-Shield, Oslo, Norway). The
buffy coats were mixed with an equal volume of phos-
phate buffered saline (PBS), pH = 7.4, layered over 3 ml
of Lymphoprep and centrifuged at 700 × g for 30 min-
utes. The recovered PBMCs were washed three times
with PBS, pH = 7.4. The monocytes were then isolated
from PBMCs by negative selection. The PBMCs were
incubated with a cocktail of biotin-conjugated antibodies
against CD3, CD7, CD16, CD19, CD56, CD123 and gly-
cophorin A and magnetic microbeads coupled to an
anti-hapten monoclonal antibody and depleted using a
magnetic column (Monocyte Isolation Kit II, Miltenyi
Biotec, Bergisch Gladbach, Germany). Purified cells were
stained for CD14, and the purity of monocytes was
determined by flow cytometry to be >98%.
Differentiation of U937 cells to macrophages
To produce macrophages, U937 cells (ATCC) were
adjusted to 2 × 10
6/ml in RPMI 1640 medium (Invitro-
gen, Carlsbad, CA) containing 10% fetal calf serum and
phorbol myristate acetate (PMA) (Sigma-Aldrich, St.
Louis, MO) at a final concentration of 2.5 ng/ml and
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Page 2 of 8incubated for 24 hours at 37°C. The adherent cells were
washed three times with PBS, pH = 7.4, to remove PMA
and incubated in culture medium containing 10% fetal
calf serum without PMA for an additional 24 hours at
37°C before being used in experiments. The maturation
of U937 cells was evaluated by measuring their CD14
expression by flow cytometry.
Ability of anti-CD14, -TLR4, and -TLR2 antibodies to
inhibit monocytes and macrophages activation
Monocytes and macrophages were cultured using RPMI
1640 medium in 96-well plates at a concentration of 2 ×
10
5/well. For blocking experiments, the monocytes and
macrophages were preincubated for 1 hour at 37°C with
10 μg/ml anti-CD14 (clone MEM18, BD Biosciences,
San Jose, CA), anti-TLR4 (clone HTA125, Santa Cruz
Biotechnology, Santa Cruz, CA), or a combination of
both antibodies for 1 hour at 37°C. After washing both
cells three times with PBS, pH = 7.4, monocytes and
macrophages were stimulated with 100 ng/ml LPS
(Sigma-Aldrich, St. Louis, MO) (positive control) for 24
hours at 37°C. Alternatively, monocytes and macro-
phages were treated with 10 μg/ml anti-TLR2 (clone
TL2.1, eBioscience, San Diego, CA) for 1 hour at 37°C
and stimulated with 20 ng/ml PamCys (synthetic lipo-
peptide Pam3Cys-Ser-Lys4) (Alexis Biochemicals, San
Diego, CA) (positive control). As an additional control,
both cells were treated with 10 μg/ml irrelevant antibo-
dies before stimulation with TLRs ligands. The culture
supernatants were collected after 24 hours of incubation
at 37°C. Secreted IL-1b, IL-6, and IL-10 levels were
determined by Cytometric Bead Array (CBA) kit (BD
Biosciences) according to the manufacturer’si n s t r u c -
tions (Additional files 1 and 2).
Blocking CD14, TLR4 and TLR2
Human monocytes (2 × 10
5/ml) and U937 cells (2 ×
10
5/ml) were treated with 10 μg/ml human anti-CD14
antibody (clone MEM18, BD Biosciences), human anti-
TLR4 antibody (clone HTA125, Santa Cruz Biotechnol-
ogy), or a combination of both antibodies for 1 hour at
37°C. After washing the cells three times with PBS, pH
= 7.4, monocytes were stimulated with 50 μg/ml
mmLDL, and macrophages were stimulated with 70 μg/
ml mmLDL for 24 hours at 37°C. Alternatively, human
monocytes (2 × 10
5/ml) and U937 cells (2 × 10
5/ml)
were incubated with 10 μg/ml anti-TLR2 (clone TL2.1,
eBioscience) for 1 hour at 37°C, washed three times
with PBS, pH = 7.4, and stimulated with 50 μg/ml
mmLDL (monocytes) or 70 μg/ml mmLDL (macro-
phages) for 24 hours at 37°C. As a positive control for
TLR4 and TLR2 activation, monocytes and macrophages
were stimulated with 100 ng/ml LPS (Sigma-Aldrich)
and 20 ng/ml PamCys (Alexis Biochemicals). As an
antibody control, cells were treated with irrelevant IgG
isotype control antibodies before stimulation with TLRs
ligands or mmLDL. As a negative control, monocytes
and U937 cells were incubated only in culture medium
or with control antibodies in the absence of TLRs agonist
or mmLDL stimulation. All supernatants were frozen at
-70°C prior to determination of cytokines secretion.
Cytokine analysis
Cytokines were measured in culture supernatants of
monocytes or macrophages treated with 50 μg/ml or 70
μg/ml mmLDL, respectively, or in cells treated with only
culture medium or with control antibodies (10 μg/ml)
using a CBA kit (BD Biosciences) and flow cytometry
analysis, according to the manufacturer’s instructions.
Briefly, the cytokine standards were diluted (5 to 5000
pg/ml). The standard dilutions and test samples were
added to the appropriate sample tubes (50 μl) and
mixed with 50 μl each of antibody-PE detector and anti-
body-bead reagent (50 μl). The mixture (150 μl) was
incubated for 3 hours in the dark at room temperature
and washed. The test samples were acquired using a
FACS Calibur flow cytometer (BD Biosciences).
Statistical analysis
The Mann-Whitney test was used to evaluate the statis-
tical significance of differences between experimental
groups. Samples with P <0 . 0 5w e r ec o n s i d e r e ds i g n i f i -
cantly different. The data shown in all figures are
expressed as the mean ± SEM of values from indepen-
dent experiments.
Results
Ability of anti-CD14, -TLR4, and -TLR2 antibodies to
inhibit monocytes and macrophages activation in
responses to LPS and Pamcys
As a positive control, we stimulated TLR4 with LPS and
TLR2 with PamCys in monocytes and macrophages. We
found that pre-treatment with anti-CD14, anti-TLR4, or
a combination of both antibodies inhibited secretion of
IL-1b (Additional file 1: Figure S1A and S1C), IL-6
(Additional file 1: Figure S1B and S1D) and IL-10 (Addi-
tional file 2: Figure S2A and S2B) in monocytes and
macrophages, respectively, stimulated with LPS. Simi-
larly, blocking TLR2 prior to PamCys stimulation inhib-
ited secretion of IL-1b (Additional file 1: Figure S1A
and S1C), IL-6 (Additional file 1: Figure S1B and S1D)
and IL-10 (Additional file 2: Figure S2A and S2B) in
monocytes and macrophages, respectively.
Inhibition of IL-1b production in monocytes and
macrophages by blocking CD14 and TLR4
Stimulation with mmLDL also induced considerable
production of IL-1b compared with the negative control
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in monocytes (Figure 1A) and macrophages (Figure 1B)
prior to mmLDL stimulus inhibited IL-1b production by
72% and 59%, respectively. Meanwhile, blocking TLR4 in
monocytes and macrophages inhibited IL-1b production
by 67% and 53%, respectively. When we blocked both
receptors in monocytes and macrophages, we found a
73% and 69% reduction, respectively, in IL-1b secretion.
Blocking CD14 and TLR4 inhibits IL-6 secretion in
monocytes and macrophages
Stimulation of monocytes and macrophages with
mmLDL caused an increase in the secretion of IL-6 at
levels higher than those observed in cells cultured only
with culture medium. Blocking CD14 in monocytes (Fig-
ure 2A) and macrophages (Figure 2B) caused a 58% and
52% reduction in IL-6 secretion, respectively. When
both cell types were treated with anti-TLR4 prior to sti-
mulation with mmLDL, IL-6 secretion was inhibited by
63% and 63%, respectively. Blocking both receptors
inhibited IL-6 secretion by 69% and 67%, respectively,
after a 24-hour culture period.
Blocking TLR2 inhibits IL-1b and IL-6 secretion in
monocytes and macrophages
Stimulation with mmLDL induced increases in IL-1b
and IL-6 secretion in monocytes and macrophages when
compared to cells cultured only with culture medium.
Preincubation with anti-TLR2 induced a 65% and 57%
reduction in IL-1b secretion in monocytes (Figure 3A)
and macrophages (Figure 3C), respectively. Similarly, the
secretion of IL-6 in response to mmLDL was reduced
by 62% and 40% in monocytes (Figure 3B) and macro-
phages (Figure 3D), respectively.
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Figure 1 Role of CD14 and TLR4 in secretion of IL-1b in response to mmLDL. Human monocytes (1A) and macrophages (1B) were treated
with anti-CD14, anti-TLR4, or both antibodies (10 μg/ml) for 1 hour before incubation with mmLDL (50 μg/ml and 70 μg/ml, respectively).
Monocytes and macrophages were incubated with irrelevant antibody (10 μg/ml) in the presence or absence of mmLDL (50 μg/ml and 70 μg/
ml, respectively). The concentration of IL-1b in culture supernatants was determined by CBA. *p < 0.005.
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Figure 2 Role of CD14 and TLR4 in secretion of IL-6 in response to mmLDL. Human monocytes (2A) and macrophages (2B) were treated
with anti-CD14, anti-TLR4, or both antibodies (10 μg/ml) for 1 hour before incubation with mmLDL (50 μg/ml and 70 μg/ml, respectively).
Monocytes and macrophages were incubated with irrelevant antibody (10 μg/ml) in the presence or absence of mmLDL (50 μg/ml and 70 μg/
ml, respectively). The concentration of IL-6 in culture supernatants was determined by CBA. *p < 0.005.
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IL-10 in response to mmLDL
Stimulation of monocytes and macrophages with
mmLDL induced secretion of IL-10 at levels higher than
those observed in cells cultured only with culture med-
ium. Blocking CD14 in monocytes (Figure 4A) and
macrophages (Figure 4C) inhibited IL-10 secretion by
63% and 65%, respectively, blocking TLR4 inhibited
IL-10 secretion by 60% and 61%, respectively, and block-
ing both receptors inhibited IL-10 secretion by 63% and
65%, respectively. Similarly, preincubation of monocytes
(Figure 4B) and macrophages (Figure 4D) with anti-
TLR2 antibody inhibited mmLDL-mediated IL-10 secre-
tion by 75% and 72%, respectively.
Discussion
Atherosclerosis is currently considered a chronic inflam-
matory disease in which monocytes and macrophages
are critical [1-3]. The possiblee t i o l o g i e so ft h i sd i s e a s e
include infections with Chlamydia pneumoniae or
responses to endogenous antigens such as LDL [5]. Sev-
eral studies have shown that the oxidized modifications
of LDL influence the development of atherosclerotic
lesions through the inflammatory response [5-7]. We
previously demonstrated that mmLDL can activate
CD14, TLR4, and TLR2, inducing TNF-a [14]. Here we
clearly demonstrate that mmLDL elicits the production
of IL-1b, IL-6, and IL-10 through CD14, TLR4, and
TLR2 in human monocytes and macrophages.
CD14 has been proposed as the first host pattern
recognition receptor involved in the recognition of most
bacterial components [19,20] and facilitates the expres-
sion of inflammatory molecules via activation of the
TLRs [21]. Our results show that monocytes and macro-
phages are activated by a very early form of oxidized LDL
via CD14, which is a necessary co-receptor for mmLDL-
mediated secretion of IL-1b and IL-6. These findings are
consistent with our previous study, in which we showed
that blocking CD14 in monocytes and macrophages sti-
mulated with mmLDL resulted in significant inhibition of
TNF-a production [14]. These results are supported by
the finding that blocking CD14 in monocytes stimulated
with extensively oxidized LDL resulted in significant inhi-
bition of IL-6 and IL-1b production [22], suggesting that
activation through the CD14 pathway plays a role in
inflammation in response to mmLDL.
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Figure 3 Role of TLR2 in secretion of IL-1b and IL-6 in response to mmLDL. Human monocytes and macrophages were treated with anti-
TLR2 (10 μg/ml) for 1 hour before stimulation with mmLDL (50 μg/ml and 70 μg/ml, respectively). Monocytes and macrophages were incubated
with irrelevant antibody (10 μg/ml) in the presence or absence of mmLDL (50 μg/ml and 70 μg/ml, respectively). The concentrations of IL-1b
and IL-6 in culture supernatants of monocytes (3A and 3B) and macrophages (3C and 3D) were determined by CBA, respectively. *p < 0.005.
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Page 5 of 8TLRs are an essential part of the innate immune sys-
tem [9,10]. Several reports indicate that TLRs can recog-
nize endogenous ligands such as heat shock protein
(HSP) 60 and hyaluronic acid, thereby inducing the
expression of TNF-a, IL-6, and other pro-inflammatory
cytokines [10,23,24]. Our results show that mmLDL
induced IL-1b and IL-6 production through TLR4. This
finding is supported by previous studies in which we
demonstrated that mmLDL induced TNF-a through
TLR4 [14]. Both of these results are supported by the
fact that blocking TLR4 inhibits TNF-a production in
cells stimulated with advanced glycation end-product of
low-density-lipoprotein [15].
The role of the CD14/TLR4 pathway in the immune
response to endogenous antigens such as mmLDL is not
well understood. Here we examined whether the activa-
tion of CD14/TLR4 induced the secretion of IL-1b and
IL-6 in cells stimulated with mmLDL. Our results
showed that mmLDL elicited the production of IL-1b
and IL-6 and that this response was inhibited when
CD14 and TLR4 were blocked. These findings are
similar to previous reports that extensively oxidized
LDL induces the secretion of IL-6 and IL-1b in mono-
cytes [22] and that blocking CD14 and TLR4 before sti-
mulation with mmLDL affects the secretion of TNF-a
[14], suggesting that the activation of the CD14/TLR4
pathway by mmLDL triggers an immune-mediated
response driving synthesis of pro-inflammatory
cytokines.
We have demonstrated that TLR2 induces TNF-a in
response to mmLDL [14]. Here we show that the secre-
tion of IL-6 and IL-1b by monocytes and macrophages
is TLR2-dependent, suggesting that TLR2 participates in
the secretion of pro-inflammatory cytokines in response
to mmLDL. This function is similar to the TLR2
response to other endogenous antigens, such as HSP60,
which also induced the secretion of TNF-a [25].
Our results indicate that the activation of CD14,
TLR4, and TLR2 on monocytes and macrophages by a
very early form of oxidized LDL induces the secretion of
pro-inflammatory cytokines such as IL-1b and IL-6,
which may contribute to or exacerbate inflammatory
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Figure 4 Role of CD14, TLR4, and TLR2 in secretion of IL-10 in response to mmLDL. Human monocytes (4A) and macrophages (4C) were
treated with anti-CD14, anti-TLR4, or both antibodies (10 μg/ml) for 1 hour before incubation with mmLDL (50 μg/ml and 70 μg/ml,
respectively). Monocytes (4B) and macrophages (4D) were treated with anti-TLR2 (10 μg/ml) for 1 hour before stimulation with mmLDL (50 μg/
ml and 70 μg/ml, respectively). Monocytes and macrophages were incubated with irrelevant antibody (10 μg/ml) in the presence or absence of
mmLDL (50 μg/ml and 70 μg/ml, respectively). The concentration of IL-10 in culture supernatants was determined by CBA. *p < 0.005.
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Page 6 of 8responses during atherosclerosis. Both of these cytokines
activate endothelial cells, inducing the expression of
chemokines such as monocyte chemoattractant protein-
1, which recruits monocytes to the lesion area, and the
upregulation of adhesion molecules, which facilitate
adhesion of leukocytes to endothelial cells [26,27].
Moreover, the exogenous administration of IL-6 exacer-
bates the atherosclerotic lesion [28], and deficiency in
IL-1b reduces atherosclerotic lesion size [29].
Previous evidence demonstrates that stimulation with
extensively oxidized LDL induces the secretion of IL-10
[30], and early forms of oxidized LDL induce an
increase in IL-10 mRNA expression in macrophages
[31]. Moreover, monocytes and macrophages secrete
IL-10 upon activation through TLR2 or TLR4 [32]. In
the present study, we found that mmLDL induced
CD14-, TLR4-, and TLR2-dependent production of IL-
10. Furthermore, we demonstrated that blocking TLR2
affected IL-10 secretion by monocytes and macrophages
more than blocking CD14, TLR4, or both CD14 and
TLR4, suggesting that mmLDL-mediated production of
IL-10 may regulate cellular activation. During the initial
activation phase, macrophages secrete pro-inflammatory
cytokines [33], and the second phase of macrophage
activation involves the delayed and gradual production
of IL-10 [34].
Conclusions
Our results establish a potential pathogenic mechanism
by which activation of CD14, TLR4, and TLR2 by
mmLDL initiates or exacerbate the pro-inflammatory
state in atherosclerotic disease.
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